Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18

British Journal of Pharmacology
Silvia CarvalhoYosef Yarden

Abstract

Antibody-based therapy of cancer employs monoclonal antibodies (mAbs) specific to soluble ligands, membrane antigens of T-lymphocytes or proteins located at the surface of cancer cells. The latter mAbs are often combined with cytotoxic regimens, because they block survival of residual fractions of tumours that evade therapy-induced cell death. Antibodies, along with kinase inhibitors, have become in the last decade the mainstay of oncological pharmacology. However, partial and transient responses, as well as emergence of tumour resistance, currently limit clinical application of mAbs. To overcome these hurdles, oligoclonal antibody mixtures are being tested in animal models and in clinical trials. The first homo-combination of two mAbs, each engaging a distinct site of HER2, an oncogenic receptor tyrosine kinase (RTK), has been approved for treatment of breast cancer. Likewise, a hetero-combination of antibodies to two distinct T-cell antigens, PD1 and CTLA4, has been approved for treatment of melanoma. In a similar vein, additive or synergistic anti-tumour effects observed in animal models have prompted clinical testing of hetero-combinations of antibodies simultaneously engaging distinct RTKs. We discuss the promise of antibo...Continue Reading

References

Jun 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·H SunadaC L MacLeod
Mar 24, 1988·Nature·L RiechmannG Winter
Dec 21, 1988·Journal of the National Cancer Institute·E Aboud-PirakM Sela
Dec 1, 1982·Proceedings of the National Academy of Sciences of the United States of America·Y TsukadaH Hirai
Jan 17, 1995·Proceedings of the National Academy of Sciences of the United States of America·G E PeoplesT J Eberlein
Jul 1, 1994·Clinical and Diagnostic Laboratory Immunology·K Kuus-ReichelN E Kay
Mar 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J BaselgaL Norton
Aug 15, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P McLaughlinB K Dallaire
Apr 29, 1999·Proceedings of the National Academy of Sciences of the United States of America·L N KlapperY Yarden
Mar 31, 2000·Nature Medicine·R A ClynesJ V Ravetch
Mar 17, 2001·Nature Reviews. Molecular Cell Biology·Y Yarden, M X Sliwkowski
Mar 20, 2001·Critical Reviews in Oncology/hematology·X D YangC G Davis
Oct 13, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J Baselga
Mar 22, 2002·Nature·Yotaro IzumiRakesh K Jain
Jan 7, 2003·Nature Medicine·Peter J Hudson, Christelle Souriau
Jul 23, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Nicola Di GaetanoJosée Golay
Sep 4, 2003·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Robert J Cersosimo
Sep 17, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wen-Kai Weng, Ronald Levy
Mar 3, 2004·World Journal of Gastroenterology : WJG·Bing-Ya LiuYan-Zhen Lin
May 12, 2004·Nature Reviews. Drug Discovery·Napoleone FerraraWilliam Novotny
Jul 23, 2004·The New England Journal of Medicine·David CunninghamEric Van Cutsem
Jul 24, 2004·Expert Review of Vaccines·Yasuhiro Oki, Anas Younes
Aug 3, 2004·Nature Reviews. Drug Discovery·Ismail Kola, John Landis
Aug 27, 2004·Proceedings of the National Academy of Sciences of the United States of America·William PaoHarold Varmus
Feb 3, 2005·Proceedings of the National Academy of Sciences of the United States of America·Lilach M FriedmanYosef Yarden
Feb 25, 2005·The New England Journal of Medicine·Susumu KobayashiBalázs Halmos

❮ Previous
Next ❯

Citations

Mar 21, 2016·Current Opinion in Immunology·Davide Corti, Jeffrey D Kearns
Jul 2, 2016·Expert Opinion on Therapeutic Patents·Tryfon Zarganes-TzitzikasAlexander Dömling
Nov 8, 2016·Expert Opinion on Biological Therapy·Panagiotis J VlachostergiosScott T Tagawa
Dec 6, 2016·Molecular Therapy : the Journal of the American Society of Gene Therapy·John A Zaia
Sep 30, 2016·PLoS Biology·Bernd L Groner, Nancy E Hynes
Dec 1, 2017·International Journal of Molecular Sciences·Emma M HaysSarah Shigdar
Jul 27, 2018·Journal of Clinical Pharmacy and Therapeutics·Gregory M PetersonInger H Olesen
Aug 10, 2018·BioTechniques·Carl A Ascoli, Birte Aggeler
Feb 6, 2020·Immunology·Simon D HardingJamie A Davies
May 30, 2020·Pharmaceuticals·Rita PeixotoMiguel Oliveira
Jul 25, 2018·Current Protocols in Bioinformatics·Joanna L SharmanUNKNOWN NC-IUPHAR
Mar 27, 2018·The Journal of Pharmacy and Pharmacology·Shima Moradi-KalbolandiLeila Farahmand
Aug 20, 2017·Protein & Cell·William R Strohl

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.

Related Papers

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Yosef Yarden, Michael Sela
European Journal of Immunology
Meghan E TurnisDario A A Vignali
Deutsche medizinische Wochenschrift
Thomas WehlerIngo Stehle
International Journal of Cancer. Journal International Du Cancer
Andreas K A GaumannGeorg Breier
© 2021 Meta ULC. All rights reserved